title: Rituximab in CD20 positive multiple myeloma.
authors.forename: P
authors.initials: P
authors.lastname: Moreau
authors.forename: L
authors.initials: L
authors.lastname: Voillat
authors.forename: L
authors.initials: L
authors.lastname: Benboukher
authors.forename: C
authors.initials: C
authors.lastname: Mathiot
authors.forename: C
authors.initials: C
authors.lastname: Dumontet
authors.forename: N
authors.initials: N
authors.lastname: Robillard
authors.forename: O
authors.initials: O
authors.lastname: Hérault
authors.forename: F
authors.initials: F
authors.lastname: Garnache
authors.forename: R
authors.initials: R
authors.lastname: Garand
authors.forename: N
authors.initials: N
authors.lastname: Varoqueaux
authors.forename: H
authors.initials: H
authors.lastname: Avet-Loiseau
authors.forename: J L
authors.initials: JL
authors.lastname: Harousseau
authors.forename: R
authors.initials: R
authors.lastname: Bataille
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use* / Q000633:toxicity; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD / Q000235:genetics; D018951:Antigens, CD20 / Q000235:genetics*; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D015972:Gene Expression Regulation, Neoplastic / Q000276:immunology; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology; D011446:Prospective Studies; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab